Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 1Breast 1

Conditions

Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × tariquidar × Genitourinary × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡